ILMN Illumina, Inc. Stock Quote

ILMN [NASD]

Healthcare | Diagnostics & Research | USA

Index	S&P 500	P/E	90.16	EPS (ttm)	4.43	Insider Own	0.30%	Shs Outstand	147.00M	Perf Week	-10.37%
Market Cap	59.16B	Forward P/E	57.92	EPS next Y	6.90	Insider Trans	-15.01%	Shs Float	145.63M	Perf Month	-9.23%
Income	656.00M	PEG	4.55	EPS next Q	1.23	Inst Own	94.00%	Short Float	2.60%	Perf Quarter	19.52%
Sales	3.24B	P/S	18.26	EPS this Y	-34.10%	Inst Trans	0.53%	Short Ratio	3.40	Perf Half Y	14.88%
Book/sh	31.93	P/B	12.52	EPS next Y	28.88%	ROA	8.90%	Target Price	413.67	Perf Year	41.64%
Cash/sh	23.45	P/C	17.04	EPS next 5Y	19.80%	ROE	14.10%	52W Range	196.78 - 555.77	Perf YTD	8.00%
Dividend	-	P/FCF	66.40	EPS past 5Y	7.40%	ROI	6.50%	52W High	-28.10%	Beta	1.02
Dividend %	-	Quick Ratio	3.30	Sales past 5Y	7.90%	Gross Margin	68.00%	52W Low	103.07%	ATR	20.07
Employees	7800	Current Ratio	3.60	Sales Q/Q	0.10%	Oper. Margin	17.90%	RSI (14)	35.52	Volatility	3.65% 4.51%
Optionable	Yes	Debt/Eq	0.25	EPS Q/Q	8.30%	Profit Margin	20.30%	Rel Volume	1.14	Prev Close	416.41
Shortable	Yes	LT Debt/Eq	0.14	Earnings	Feb 11 AMC	Payout	0.00%	Avg Volume	1.12M	Price	399.61
Recom	2.70	SMA20	-12.48%	SMA50	-3.86%	SMA200	10.66%	Volume	1,266,985	Change	-4.03%

Mar-03-21

Initiated

Barclays

Underweight

$325

Dec-22-20

Upgrade

Piper Sandler

Neutral → Overweight

$340 → $415

Dec-17-20

Upgrade

BTIG Research

Neutral → Buy

$410

Oct-13-20

Downgrade

Guggenheim

Buy → Neutral

Sep-30-20

Initiated

Atlantic Equities

Overweight

$355

Sep-29-20

Downgrade

Wolfe Research

Outperform → Peer Perform

Sep-22-20

Downgrade

UBS

Buy → Neutral

$390 → $285

Sep-22-20

Downgrade

Stifel

Buy → Hold

$380 → $280

Sep-21-20

Upgrade

Guggenheim

Neutral → Buy

$345

Sep-21-20

Downgrade

JP Morgan

Overweight → Neutral

$390 → $280

Sep-09-20

Initiated

Morgan Stanley

Equal-Weight

$400

Aug-07-20

Downgrade

Piper Sandler

Overweight → Neutral

$356 → $340

Aug-07-20

Downgrade

Evercore ISI

In-line → Underperform

$310

Jul-07-20

Downgrade

Guggenheim

Buy → Neutral

Apr-24-20

Downgrade

Citigroup

Buy → Neutral

$250 → $320

Apr-21-20

Downgrade

Robert W. Baird

Outperform → Neutral

$310

Jan-08-20

Initiated

Wells Fargo

Underweight

$300

Jan-07-20

Initiated

Citigroup

Buy

$385

Jan-02-20

Downgrade

Evercore ISI

Outperform → In-line

$330 → $340

Nov-15-19

Initiated

Stifel

Buy

Mar-05-21 01:00AM	Illumina and R-Pharm Secure Registration for Two Complete IVD Sequencing Platforms in Russia Business Wire
Mar-02-21 07:05AM	Myriad Genetics Joins Forces with Intermountain Precision Genomics for a Comprehensive Offering of Germline and Somatic Tumor Testing Services GlobeNewswire
Feb-22-21 07:00PM	Genomic sequencing head calls for Bio Force to detect virus threats Financial Times
Feb-19-21 12:29PM	Is Illumina (ILMN) Stock a Buy For 2021? Insider Monkey
01:00AM	Illumina and the University Hospital of Tübingen Evaluate Potential of Whole Genome Sequencing to Improve Diagnosis of Full Range of Genetic Diseases Business Wire
Feb-16-21 12:48PM	Is Illumina (ILMN) Stock a Buy For 2021? Insider Monkey
Feb-15-21 02:58AM	Illumina Rockets After Topping Q4 Earnings FX Empire
Feb-12-21 04:21PM	Illumina Stock: Covid, Bioterrorism And Grail Just Sent It To A Record Investor's Business Daily +11.87%
02:52PM	Why These 2 Hot Nasdaq Stocks Are Soaring Friday Motley Fool
12:00PM	Why Illumina Stock Is Skyrocketing Today Motley Fool
10:27AM	Illumina Reports Better-Than-Expected Q4 Earnings; Shares Slip Pre-Market SmarterAnalyst
09:17AM	Illumina (ILMN) Q4 Earnings Top Estimates, Margins Decline Zacks
07:56AM	5 Top Stock Gainers for Friday: Fisker, HubSpot, Illumina TheStreet.com
07:36AM	Illumina Surges After Strong Earnings, Price Target Upgrades TheStreet.com
Feb-11-21 10:31PM	Illumina Inc (ILMN) Q4 2020 Earnings Call Transcript Motley Fool
05:35PM	Illumina (ILMN) Q4 Earnings and Revenues Beat Estimates Zacks
04:56PM	Medical Stock Beats Views, But Shares Dip On Disappointing 2021 Outlook Investor's Business Daily
04:20PM	Recap: Illumina Q4 Earnings Benzinga
04:05PM	Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2020 Business Wire
03:15PM	Illumina, Inc. to Host Earnings Call ACCESSWIRE
Feb-10-21 10:47AM	A Preview Of Illumina's Earnings Benzinga
07:00AM	Illumina to Webcast Upcoming Investor Conference Presentations Business Wire
05:20AM	SoftBank To Invest $900M In Pacific Biosciences - WSJ Benzinga
Feb-08-21 01:35PM	Polen Capital: Illumina (ILMN) Poised to Become Even Larger and Stronger in $20B DNA Sequencing Market Insider Monkey +5.16%
09:15AM	Illumina (ILMN) to Report Q4 Earnings: What's in the Offing? Zacks
09:05AM	Illumina Accelerator Invests in Nine Genomics Startups for Second Global Cycle Business Wire
08:42AM	Why Shares of Illumina Rose 15.3% in January Motley Fool
Feb-04-21 05:00AM	Illumina Supports National Program to Evaluate Potential of Comprehensive Genomic Profiling in Late Stage Cancer Real-World Setting Across Belgium Business Wire
Feb-02-21 06:12AM	Is Pacific Biosciences of California a Ticking Time Bomb for Investors? Motley Fool
Feb-01-21 09:36AM	Illumina (ILMN) New Collaboration to Aid Genomics Startups Zacks
06:08AM	2 Stocks That Wall Street Hates but You'll Probably Like Motley Fool
Jan-31-21 07:00PM	Illumina and Sequoia Capital China Partner to Launch Genomics Incubator in China Business Wire
Jan-27-21 06:10AM	Should You Buy Bionano Genomics Stock? Motley Fool
Jan-25-21 10:00AM	Illumina to Announce Fourth Quarter & Full Year 2020 Financial Results on Thursday, February 11, 2021 Business Wire
08:21AM	Baidu, Illumina, American Axle & Manufacturing, International Paper and KB Home highlighted as Zacks Bull and Bear of the Day Zacks
04:20AM	Bear of the Day: Illumina (ILMN) Zacks
Jan-22-21 07:57AM	Illumina (ILMN) is in Overbought Territory: What's Next? Zacks
01:02AM	The Illumina (NASDAQ:ILMN) Share Price Is Up 162% And Shareholders Are Boasting About It Simply Wall St.
Jan-20-21 04:05PM	Illumina Wins Patent Infringement Suit against BGI in the UK Business Wire
Jan-15-21 02:16PM	Fear of new virus variant pushes U.S. toward more genomic sequencing MarketWatch
Jan-14-21 08:29AM	New Strong Sell Stocks for January 14th Zacks
Jan-13-21 08:09AM	3 Top Biotech Picks for January Motley Fool
Jan-12-21 08:40AM	Myriad Genetics (MYGN), Illumina Partner to Enhance Oncology Arm Zacks
Jan-11-21 03:42PM	Illumina CEO Says Business Is Bouncing Back. The Gene Sequencer Sees New Opportunities. Barrons.com
02:10PM	New Bioinformatics Solution Powers Multi-Omics Discovery at Massive Scale Business Wire
02:05PM	Myriad Genetics Forms Strategic Partnership with Illumina in Oncology GlobeNewswire
02:05PM	Illumina Announces New and Expanded Oncology Partnerships with Bristol Myers Squibb, Kura Oncology, Myriad Genetics, and Merck to Advance Comprehensive Genomic Profiling Business Wire
10:12AM	Illumina (ILMN), Helix Partner to Develop Tracking Setup in U.S. Zacks
Jan-08-21 07:00AM	Why The Covid Pandemic Will Be A Boon For These Health Care Stocks Investor's Business Daily
Jan-07-21 01:18PM	12 Best Telemedicine Stocks to Buy Now Insider Monkey
Jan-06-21 07:30AM	The Daily Biotech Pulse: Aerpio Reviews Strategic Options, Hologic Goes Shopping Benzinga
Jan-05-21 07:00PM	Illumina and Helix Collaborate to Assess Prevalence of New SARS-CoV-2 UK Variant (B.1.1.7) in the US and Develop National Surveillance Infrastructure Business Wire
08:19AM	Active Traders Look to Biotech for 2021 Investopedia
Dec-31-20 09:39AM	Here's Why You Should Hold on to Illumina (ILMN) Stock for Now Zacks
Dec-26-20 02:23PM	15 Best Fictional Companies in the World Insider Monkey
Dec-22-20 06:58PM	10 Best Stocks in the Nasdaq on Tuesday: Workday Climbs TheStreet.com
07:00AM	Illumina to Webcast Upcoming Investor Conference Presentations Business Wire
Dec-15-20 01:26AM	Should You Think About Buying Illumina, Inc. (NASDAQ:ILMN) Now? Simply Wall St.
Dec-09-20 12:33PM	Want to Buy Illumina (ILMN) Stock? Heres What You Need to Know Insider Monkey
08:18AM	Illumina (ILMN)-Harvard Pilgrim Partner to Expand WGS Access Zacks
Dec-08-20 04:05PM	Illumina and Harvard Pilgrim Health Care Expand Access to Whole-Genome Sequencing for Genetic Disease Testing Business Wire
12:30PM	Is Illumina (ILMN) a Smart Long-term Buy? Insider Monkey
Dec-04-20 08:15PM	Is Illumina a Buy Following UK NHS Partnership? Analyst Weighs In SmarterAnalyst
Dec-03-20 05:09PM	Scottish Warlords of Investing: Baillie Gifford Sells TSLA, Buys TTD, Holds SHOP Zacks
Nov-24-20 02:44PM	Precision Medicine is Coming. What That Means for Patients and Investors. Barrons.com
10:31AM	Here's Why You Should Hold on to Illumina (ILMN) Stock for Now Zacks
Nov-18-20 07:00AM	Illumina to Webcast Upcoming Investor Conference Presentation Business Wire
Nov-13-20 08:30AM	Wild Ride For Illumina Stock Shows Promise, Challenge Of Multi-Cancer Blood Tests Investor's Business Daily
Nov-12-20 08:00PM	Realize the Full Potential of the NextSeq 2000 with the Power of the P3 Reagent Kit Business Wire
04:05PM	Realize the Full Potential of the NextSeq 2000 with the Power of the P3 Reagent Kit Business Wire
03:55PM	Coronavirus Vaccine News Puts This Biotech Stock In Focus Is It A Buy Right Now? Investor's Business Daily
03:15PM	Twist Bioscience, Illumina and Western Digital Form Alliance with Microsoft to Advance Data Storage in DNA Business Wire
Nov-09-20 08:48AM	Will Weakness in Illumina, Inc.'s (NASDAQ:ILMN) Stock Prove Temporary Given Strong Fundamentals? Simply Wall St.
Nov-02-20 12:34PM	Illumina (ILMN) Q3 Earnings Top Estimates, Margins Decline Zacks
Oct-31-20 07:44AM	3 Unstoppable Stocks To Buy Before or After the Election Motley Fool
Oct-30-20 06:05AM	Why Illumina's Q3 Results Were Better Than They Might Seem Motley Fool -7.05%
12:03AM	Illumina Inc (ILMN) Q3 2020 Earnings Call Transcript Motley Fool
Oct-29-20 06:05PM	Illumina (ILMN) Q3 Earnings and Revenues Surpass Estimates Zacks
05:11PM	Illumina: Q3 Earnings Insights Benzinga
04:05PM	Illumina Reports Financial Results for Third Quarter of Fiscal Year 2020 Business Wire
03:15PM	Illumina, Inc. to Host Earnings Call ACCESSWIRE
07:30AM	Zacks.com featured highlights include: StoneCo, Las Vegas Sands, Yandex and Illumina Zacks
Oct-28-20 11:53AM	4 Toxic Stocks That You Need to be Wary of & Dump Right Now Zacks
06:57AM	Better Buy: Illumina vs. Exelixis Motley Fool
Oct-27-20 06:05PM	Was The Smart Money Right About Illumina, Inc. (ILMN)? Insider Monkey
12:44PM	Exact Sciences Soars on $2.15 Billion Deal for Testing Firm Bloomberg
Oct-26-20 12:00PM	Why Illumina (ILMN) Stock is a Compelling Investment Case Insider Monkey
11:40AM	CHRS or ILMN: Which Is the Better Value Stock Right Now? Zacks
07:28AM	Why a Student of Disruptive Innovation Is Betting on Tesla, Telehealth, and Genomics Barrons.com
Oct-23-20 09:03AM	Illumina (ILMN) to Report Q3 Earnings: What's in the Offing? Zacks
Oct-22-20 12:33PM	Analysts Estimate Illumina (ILMN) to Report a Decline in Earnings: What to Look Out for Zacks
Oct-20-20 06:12AM	The 1 Stock Most Likely to Win From a Potentially Game-Changing Coronavirus Discovery Motley Fool
Oct-10-20 07:03AM	Next Coronavirus Market Correction: Where to Invest $5,000 Motley Fool
Oct-04-20 12:00PM	Why Ilumina's Stock Fell 13.5% in September Motley Fool
10:08AM	How to compare data that change over time Quartz
Oct-02-20 05:11PM	Analyst Report: Illumina, Inc. CoinDesk
Oct-01-20 02:22PM	7 Diagnostic and Genomic Stocks Storming Into October Zacks
Sep-30-20 09:35AM	Benzinga's Top Upgrades, Downgrades For September 30, 2020 Benzinga
06:04AM	Better Buy: Invitae vs. Illumina Motley Fool
Sep-28-20 07:00AM	Illumina to Announce Third Quarter 2020 Financial Results on Thursday, October 29, 2020 Business Wire

Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is headquartered in San Diego, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
FLATLEY JAY T	Director	Mar 02	Sale	444.61	4,000	1,778,440	168,933	Mar 04 05:04 PM
MCGINNIS KAREN K	VP, Chief Accounting Officer	Feb 18	Sale	486.75	666	324,176	1,538	Feb 22 05:11 PM
TOUSI SUSAN H	SVP Product Development	Feb 17	Option Exercise	0.00	6,306	0	48,921	Feb 18 04:52 PM
SAMAD SAM	SVP and CFO	Feb 17	Option Exercise	0.00	4,379	0	9,355	Feb 18 04:51 PM
RAGUSA ROBERT P	SVP, Global Quality & Ops	Feb 17	Option Exercise	0.00	6,306	0	12,795	Feb 18 04:49 PM
MCGINNIS KAREN K	VP, Chief Accounting Officer	Feb 17	Option Exercise	0.00	935	0	2,576	Feb 18 04:47 PM
Hoyt Aimee L	SVP, Chief People Officer	Feb 17	Option Exercise	0.00	4,625	0	8,873	Feb 18 04:45 PM
Febbo Phillip G.	SVP Chief Medical Officer	Feb 17	Option Exercise	0.00	3,173	0	7,046	Feb 18 04:44 PM
deSouza Francis A	President and CEO	Feb 17	Option Exercise	0.00	24,521	0	85,934	Feb 18 04:42 PM
Dadswell Charles	SVP & General Counsel	Feb 17	Option Exercise	0.00	3,503	0	8,781	Feb 18 04:41 PM
FLATLEY JAY T	Director	Feb 16	Sale	495.09	500	247,543	3,500	Feb 18 07:08 PM
FLATLEY JAY T	Director	Feb 16	Sale	505.26	4,000	2,021,040	172,933	Feb 18 07:08 PM
TOUSI SUSAN H	SVP Product Development	Feb 05	Sale	431.90	800	345,520	39,713	Feb 09 04:48 PM
Hoyt Aimee L	SVP, Chief People Officer	Feb 02	Sale	444.84	57	25,356	2,359	Feb 03 05:00 PM
FLATLEY JAY T	Director	Feb 02	Sale	444.84	4,000	1,779,360	176,933	Feb 03 04:58 PM
MCGINNIS KAREN K	VP, Chief Accounting Officer	Feb 02	Sale	444.84	72	32,028	1,538	Feb 03 04:57 PM
deSouza Francis A	President and CEO	Feb 01	Sale	439.78	3,000	1,319,330	52,603	Feb 03 04:56 PM
TOUSI SUSAN H	SVP Product Development	Jan 20	Sale	400.00	2,500	1,000,000	40,447	Jan 21 04:40 PM
FLATLEY JAY T	Director	Jan 19	Sale	382.48	4,000	1,529,920	180,933	Jan 21 04:38 PM
Hoyt Aimee L	SVP, Chief People Officer	Jan 11	Sale	379.65	271	102,885	2,359	Jan 12 04:41 PM
TOUSI SUSAN H	SVP Product Development	Jan 05	Sale	365.27	300	109,581	42,947	Jan 06 07:20 PM
FLATLEY JAY T	Director	Jan 05	Sale	365.27	4,000	1,461,080	184,933	Jan 06 07:19 PM
deSouza Francis A	President and CEO	Jan 04	Sale	370.51	3,000	1,111,537	55,540	Jan 06 07:17 PM
FLATLEY JAY T	Director	Dec 15	Sale	348.84	4,000	1,395,360	188,933	Dec 16 06:07 PM
Hoyt Aimee L	SVP, Chief People Officer	Dec 14	Sale	345.00	354	122,130	2,744	Dec 16 06:05 PM
Ronaghi Mostafa	SVP, Entrepreneurial Devlopmt	Dec 10	Sale	338.58	5,000	1,692,922	80,162	Dec 14 04:12 PM
TOUSI SUSAN H	SVP Product Development	Dec 07	Sale	349.34	300	104,803	43,247	Dec 08 05:34 PM
TOUSI SUSAN H	SVP Product Development	Dec 04	Sale	350.00	200	70,000	43,547	Dec 08 05:34 PM
Dadswell Charles	SVP & General Counsel	Dec 01	Sale	323.86	1,694	548,619	3,460	Dec 02 05:48 PM
deSouza Francis A	President and CEO	Dec 01	Sale	327.95	3,000	983,851	58,540	Dec 02 05:45 PM
TOUSI SUSAN H	SVP Product Development	Dec 01	Sale	325.00	100	32,500	43,747	Dec 02 05:41 PM
FLATLEY JAY T	Director	Dec 01	Sale	323.90	4,000	1,295,590	192,933	Dec 02 05:37 PM
RAGUSA ROBERT P	SVP, Global Quality & Ops	Nov 30	Sale	314.82	2,890	909,827	4,092	Dec 02 05:34 PM
MCGINNIS KAREN K	VP, Chief Accounting Officer	Nov 18	Sale	300.00	218	65,400	1,538	Nov 19 04:16 PM
FLATLEY JAY T	Director	Nov 17	Sale	297.16	3,000	891,470	196,933	Nov 19 04:18 PM
MCGINNIS KAREN K	VP, Chief Accounting Officer	Nov 06	Sale	310.10	312	96,751	1,872	Nov 09 05:40 PM
Hoyt Aimee L	SVP, Chief People Officer	Nov 06	Sale	310.10	215	66,672	3,098	Nov 09 05:39 PM
Febbo Phillip G.	SVP Chief Medical Officer	Nov 06	Sale	310.10	155	48,066	2,143	Nov 09 05:35 PM
FLATLEY JAY T	Director	Nov 03	Sale	297.34	3,000	892,010	199,933	Nov 04 04:43 PM
deSouza Francis A	President and CEO	Nov 02	Sale	300.28	3,000	900,852	65,840	Nov 04 04:39 PM
Dadswell Charles	SVP & General Counsel	Nov 02	Sale	298.00	121	36,058	6,036	Nov 04 04:34 PM
FLATLEY JAY T	Director	Oct 20	Sale	321.72	4,000	1,286,860	202,933	Oct 22 03:47 PM
TOUSI SUSAN H	SVP Product Development	Oct 12	Sale	350.00	200	70,000	44,968	Oct 14 04:07 PM
TOUSI SUSAN H	SVP Product Development	Oct 07	Sale	325.00	100	32,500	45,168	Oct 08 05:21 PM
FLATLEY JAY T	Director	Oct 07	Sale	324.01	1,000	324,010	206,933	Oct 08 05:18 PM
FLATLEY JAY T	Director	Oct 06	Sale	317.79	3,000	953,370	207,933	Oct 07 04:49 PM
deSouza Francis A	President and CEO	Oct 01	Sale	308.78	3,000	926,331	68,840	Oct 05 05:14 PM
Dadswell Charles	SVP & General Counsel	Oct 01	Sale	312.82	121	37,851	6,157	Oct 05 05:11 PM
FLATLEY JAY T	Director	Sep 15	Sale	355.22	4,000	1,420,880	210,933	Sep 17 04:59 PM
TOUSI SUSAN H	SVP Product Development	Sep 09	Sale	350.00	200	70,000	45,268	Sep 10 04:49 PM
TOUSI SUSAN H	SVP Product Development	Sep 08	Sale	336.00	100	33,600	45,468	Sep 10 04:49 PM
Van Oene Mark	SVP Chief Commercial Officer	Sep 01	Sale	355.13	625	221,953	17,648	Sep 02 07:52 PM
deSouza Francis A	President and CEO	Sep 01	Sale	352.32	3,000	1,056,964	71,840	Sep 02 07:49 PM
Dadswell Charles	SVP & General Counsel	Sep 01	Sale	355.35	1,687	599,475	6,278	Sep 02 07:45 PM
FLATLEY JAY T	Director	Sep 01	Sale	355.35	4,000	1,421,400	214,933	Sep 02 07:35 PM
RAGUSA ROBERT P	SVP, Global Quality & Ops	Aug 31	Sale	355.18	5,000	1,775,907	8,103	Sep 02 07:29 PM
FLATLEY JAY T	Director	Aug 18	Sale	354.03	4,000	1,416,120	218,933	Aug 20 05:14 PM
MCGINNIS KAREN K	VP, Chief Accounting Officer	Aug 10	Sale	357.01	1,856	662,611	2,350	Aug 12 04:32 PM
TOUSI SUSAN H	SVP Product Development	Aug 05	Sale	399.03	800	319,220	45,568	Aug 06 04:21 PM
Hoyt Aimee L	SVP, Chief People Officer	Aug 04	Sale	397.73	29	11,534	3,498	Aug 05 05:57 PM
FLATLEY JAY T	Director	Aug 04	Sale	397.73	4,000	1,590,920	222,933	Aug 05 05:54 PM
deSouza Francis A	President and CEO	Aug 03	Sale	389.85	3,000	1,169,543	74,822	Aug 05 04:57 PM
Van Oene Mark	SVP Chief Commercial Officer	Aug 03	Sale	385.43	625	240,894	18,255	Aug 05 05:50 PM
Dadswell Charles	SVP & General Counsel	Aug 03	Sale	385.19	121	46,608	7,913	Aug 05 05:41 PM
FLATLEY JAY T	Director	Jul 21	Sale	399.00	4,000	1,596,000	226,933	Jul 22 04:46 PM
TOUSI SUSAN H	SVP Product Development	Jul 20	Sale	400.00	500	200,000	46,354	Jul 22 04:49 PM
FLATLEY JAY T	Director	Jul 07	Sale	370.22	4,000	1,480,880	230,933	Jul 08 04:52 PM
TOUSI SUSAN H	SVP Product Development	Jul 06	Sale	375.00	300	112,500	46,854	Jul 08 04:40 PM
Dadswell Charles	SVP & General Counsel	Jul 01	Sale	369.26	121	44,680	8,034	Jul 06 04:07 PM
Van Oene Mark	SVP Chief Commercial Officer	Jul 01	Sale	369.40	625	230,874	18,880	Jul 06 04:25 PM
deSouza Francis A	President and CEO	Jul 01	Sale	366.65	3,000	1,099,960	78,158	Jul 06 04:13 PM
FLATLEY JAY T	Director	Jun 16	Sale	354.93	4,000	1,419,720	234,933	Jun 17 04:18 PM
RAGUSA ROBERT P	SVP, Global Quality & Ops	Jun 15	Sale	340.76	5,000	1,703,809	13,056	Jun 17 04:15 PM
Hoyt Aimee L	SVP, Chief People Officer	Jun 08	Sale	350.94	191	67,030	3,498	Jun 10 05:09 PM
FLATLEY JAY T	Director	Jun 02	Sale	364.40	4,000	1,457,600	238,933	Jun 03 04:37 PM
deSouza Francis A	President and CEO	Jun 01	Sale	362.78	3,000	1,088,329	81,158	Jun 03 04:34 PM
Van Oene Mark	SVP Chief Commercial Officer	Jun 01	Sale	361.54	625	225,963	19,505	Jun 03 04:27 PM
Dadswell Charles	SVP & General Counsel	Jun 01	Sale	362.60	1,686	611,344	8,155	Jun 03 04:25 PM
TOUSI SUSAN H	SVP Product Development	May 28	Sale	375.00	600	225,000	47,154	Jun 01 04:34 PM
SAMAD SAM	SVP and CFO	May 26	Sale	360.00	1,356	488,160	3,879	May 28 06:20 PM
TOUSI SUSAN H	SVP Product Development	May 20	Sale	350.00	300	105,000	47,754	May 21 04:51 PM
FLATLEY JAY T	Director	May 19	Sale	342.34	4,000	1,369,360	241,970	May 20 06:48 PM
SAMAD SAM	SVP and CFO	May 18	Sale	340.00	1,357	461,380	5,235	May 20 06:50 PM
TOUSI SUSAN H	SVP Product Development	May 12	Sale	325.00	600	195,000	48,054	May 13 06:08 PM
OSTADAN OMEAD	SVP Mktg, Prod & Strat Plan	May 11	Sale	315.13	2,140	674,369	17,172	May 13 06:04 PM
ARNOLD FRANCES	Director	May 11	Sale	309.11	1,503	464,592	9,954	May 13 05:57 PM
FLATLEY JAY T	Director	May 05	Sale	310.37	3,000	931,110	245,970	May 07 05:57 PM
Van Oene Mark	SVP Chief Commercial Officer	May 01	Sale	316.83	625	198,016	20,130	May 05 07:01 PM
deSouza Francis A	President and CEO	May 01	Sale	308.61	3,000	925,819	84,158	May 05 06:35 PM
Dadswell Charles	SVP & General Counsel	May 01	Sale	317.16	121	38,376	9,841	May 05 06:22 PM
FLATLEY JAY T	Director	Apr 21	Sale	310.77	3,000	932,310	248,970	Apr 22 04:52 PM
SAMAD SAM	SVP and CFO	Apr 20	Sale	320.02	1,356	433,947	6,592	Apr 22 04:54 PM
SAMAD SAM	SVP and CFO	Apr 16	Sale	300.00	1,697	509,100	7,948	Apr 20 05:41 PM
Febbo Phillip G.	SVP Chief Medical Officer	Apr 16	Sale	300.00	173	51,900	2,490	Apr 20 05:39 PM
Van Oene Mark	SVP Chief Commercial Officer	Apr 16	Sale	300.22	1,250	375,275	20,755	Apr 20 05:37 PM
SAMAD SAM	SVP and CFO	Apr 14	Sale	292.54	249	72,842	9,645	Apr 16 04:25 PM
FLATLEY JAY T	Director	Apr 07	Sale	284.63	2,000	569,260	251,970	Apr 08 05:37 PM
deSouza Francis A	President and CEO	Apr 06	Sale	275.00	3,000	825,000	87,158	Apr 07 04:26 PM
Dadswell Charles	SVP & General Counsel	Apr 01	Sale	265.92	121	32,176	9,962	Apr 03 04:38 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience